Related Experiment Video

Updated: Jun 27, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Modulation of DNA damage checkpoint; patenting and possible application for cancer medicine

Kazuhiro Ishikawa1, Hideshi Ishii, Keiichi Ichimura

  • 1Department of Otolaryngology-Head and Neck Surgery, Center for Molecular Medicine, Jichi Medical University School of Medicine, Tochigi 329-0498, Japan. kazu-ish@jichi.ac.jp

Recent Patents on DNA & Gene Sequences
|December 17, 2008
PubMed

Insights

Eukaryote cells use DNA damage checkpoints to maintain genomic integrity. Targeting the Rad9-Chk1 pathway offers potential for cancer medicine by modulating these checkpoints for repair or cell death.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Eukaryote cells possess checkpoint mechanisms to detect and respond to DNA damage or replication stress.
  • These checkpoints halt cell cycle progression, allowing for DNA repair and completion of replication.
  • Cancer cells often evade these checkpoints, contributing to tumor development.

Purpose of the Study:

  • To review recent advancements in understanding DNA damage checkpoints.
  • To discuss patenting activities related to modulating these pathways.
  • To explore potential applications in cancer medicine.

Main Methods:

  • Literature review of recent progress in DNA damage checkpoint research.
  • Analysis of patent landscape concerning checkpoint modulation.
  • Discussion of therapeutic strategies targeting DNA damage response pathways.

Main Results:

  • The Rad9-Chk1 pathway is a key focus in DNA damage checkpoint modulation.
  • Understanding these pathways is crucial for developing novel cancer therapies.
  • Targeting DNA damage response can lead to either repair or cell death, impacting cancer treatment.

Conclusions:

  • Modulating DNA damage checkpoints, particularly the Rad9-Chk1 pathway, holds significant promise for cancer medicine.
  • Therapeutic strategies can be designed to exploit these mechanisms for cancer detection, diagnosis, and treatment.
  • Further research and patenting in this area are vital for clinical translation.

More Related Videos

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...